Management & Directors

John McDermott is President and Chief Executive Officer and a member of the Endologix Board of Directors. He joined Endologix in 2008 after spending 12 years at C.R. Bard (NYSE: BCR) in various leadership roles including President of Bard Peripheral Vascular, President of Global Sales for Vascular Surgery and Endovascular, and President of IMPRA, Inc. Prior to Bard he was the Chief Operating Officer of IMPRA, a private medical device company that was sold to Bard in 1996. Mr. McDermott joined IMPRA in 1990 as Chief Financial Officer after working for seven years in commercial banking. He is active in the medical device industry and currently serves on the Board of the Directors for the International Society of Endovascular Specialists. Mr. McDermott has three issued U.S. patents, a BS in Finance from Arizona State University, and an MBA from Western International University.

Todd Abraham joined us in July 2010 as Vice President of Operations. He has more than 25 years of experience in the medical device industry, with direct experience in manufacturing, operational management and commercialization. Prior to joining Endologix, he held several management positions at Edwards Lifesciences, including Vice President, Glucose Monitoring; Vice President, Global Supply Chain & Logistics; and Vice President, Manufacturing. Prior to joining Edwards, he was Vice President & General Manager of Sterilis, Inc., a development stage start-up focused on minimally invasive products for gynecology, urology and general surgery. He began his career at Cordis Corporation (acquired by Johnson & Johnson in 1996), where he spent 14 years in positions of increasing responsibility, gaining operational and product development experience across several cardiovascular product categories and manufacturing lines. He received a B.A. in Economics from Duke University and completed graduate work in Engineering Management at the University of South Florida.

Joseph A. DeJohn joined us in July 2008 as Vice President of Sales. He has more than 20 years of sales management experience in the medical device industry, including serving 17 years at C.R. Bard Corporation. During his tenure at C.R. Bard, he held sales management positions with increasing responsibilities, serving the last six years as Vice President of Sales of the Peripheral Vascular Division. In this position, he was responsible managing a 200-person sales organization and played a leadership role in strategic planning, budgeting, recruitment, professional development, national accounts and customer service. Prior to that, Mr. DeJohn was Director of Sales of C.R. Bard's Peripheral Technologies Division. Before joining C.R. Bard, Mr. DeJohn served five years with Bausch & Lomb Corporation in various sales management positions. He received a B.S. in education from Bowling Green State University.

Janet Fauls joined us in November 2005 as our Director of Regulatory Affairs, and Quality Assurance. In July 2007, she was promoted to Senior Director of Clinical and Regulatory Affairs. Effective November 16, 2007, she was promoted to serve as our Vice President, Regulatory, Quality and Clinical Affairs. Ms. Fauls has more than 20 years of experience in the medical device and biopharmaceutical industries. From 1987 to 1997, Ms. Fauls held increasingly responsible positions in Quality and Regulatory Affairs for Allergan, Inc. and Alliance Pharmaceuticals. From 1997 to 2001, Ms. Fauls served in a Regulatory Affairs management capacity at Edwards Lifesciences with primary responsibility for surgical heart valve repair and replacement products and related disposable products. From 2001 to November 2005, Ms. Fauls served as Vice President, Regulatory, Quality and Clinical Affairs for Cardiogenesis Corporation, a medical device company specializing in laser-based cardiovascular therapies. Ms. Fauls received a BS in Chemistry from University of California, Santa Barbara.

Robert J. Krist joined us in August 2004 and serves as our Chief Financial Officer and Secretary. Mr. Krist served as Chief Financial Officer of CardioNet, Inc. from March 2003 until May 2004. Mr. Krist previously served for three years as Chief Financial Officer of Irvine-based Datum, Inc., a technology manufacturer. Prior to that, Mr. Krist served for three years as Chief Financial Officer and Vice President, Field Operations, of Bridge Medical, Inc., a start-up pharmacy information systems company. Mr. Krist also held various management positions during his six years at McGaw, Inc., including Chief Financial Officer and President of the Central Admixture Pharmacy Services Division. Mr. Krist received a BS in physics from Villanova University and an MBA from the University of Southern California.

Ruth Lyons joined us in August 2011 as Vice President of Global Marketing. Previously, Ms. Lyons spent 10 years in leadership positions in marketing, portfolio planning and business development at St. Jude Medical's Cardiac Rhythmn Management Division. Most recently Ms. Lyons held the position of VP Marketing, Emerging Technologies where she had primary responsibilities for all product planning and marketing of new technologies and future growth drivers. Prior to St. Jude Medical, Ms. Lyons held senior marketing positions at Johnson & Johnson's Cordis Cardiology, Biosense Webster and DePuy Orthopaedics divisions as well as 10 years in sales and marketing at Baxter Healthcare. Ms. Lyons has a Masters in Business Administration from the University of Southern California.

Robert Mitchell joined Endologix December 2010 as President Global Strategic Initiatives. He has over twenty years of professional experience leading several high technology medical device companies. Most recently, Mr. Mitchell was President and CEO of Nellix Endovascular, prior to its acquisition by Endologix. Prior to joining Nellix, Mr. Mitchell served as Chief Operating Officer & Executive Vice President at AngioDynamics, a NASDAQ-listed public company and leading provider of innovative medical devices to treat cancer and peripheral vascular disease. Mr. Mitchell also served as Chairman, President and Chief Executive Officer of Millimed Holdings, Inc., a privately-held company based in Roskilde, Denmark, developing next-generation drug eluting products centered on the treatment of vascular disease. Much of Mr. Mitchell's professional experience was at Cook Medical Inc., the world's largest privately-held medical device company, where he was responsible for various operations from 1986 to 2002. As Senior Vice President, he led Cook's largest revenue generating business units including: interventional radiology, cardiology, endovascular, critical care and surgical. Directly following this position, he was recruited by NASDAQ-listed Align Technology, Inc. of Santa Clara, California, where he was Vice President of Worldwide Sales and a member of the Executive Management Committee.

Mr. Mitchell received his Bachelor of Science degree from the University of Utah and his MBA from Indiana Wesleyan University.

Stefan G. Schreck, Ph.D. joined us in February 2004 and serves as our Vice President of Technology. Dr. Schreck has more than 20 years of experience in research and development of medical products. Prior to joining us, Dr. Schreck held increasingly more responsible R&D management positions in the medical device industry. From May 1995 to April 2000, Dr. Schreck served as Director of Research in Baxter Healthcare's Heart Valve Division. From April 2000 to August 2002, Dr. Schreck served as Senior Director R&D at Edwards Lifesciences and was responsible for the development of all surgical heart valve repair and replacement products. From August 2002 to February 2004, Dr. Schreck served as President & CEO of MediMorph Solutions Inc., an engineering and management consulting firm for the medical device industry that he founded.

Gary I. Sorsher joined us in October 2008 as Vice President, Quality, bringing 20 years of quality assurance experience. Prior to joining Endologix, he served for two years as Director of Quality Engineering at Bard Peripheral Vascular, where he oversaw quality assurance operations for Bard Peripheral Vascular and Bard Biopsy Systems. Prior to that, he spent 13 years at Cordis, a Johnson & Johnson Company, holding several positions with increasing responsibility during his tenure. Among these, he served as Director of Quality Assurance – New Product Development and as the senior quality assurance representative for Cordis' Global Commercialization Team responsible for drug eluting stents, stent delivery systems and angioplasty products. Mr. Sorsher received a Master of Science and Bachelor of Science in electrical engineering from Byelorussian Polytechnic Institute, USSR.

Franklin D. Brown serves as our Chairman and has been a director since 2002, and was formerly a director of the private company Endologix, Inc. from 1997 to 2002. Following the merger with the former Endologix in May 2002, Mr. Brown was our Chief Executive Officer and Chairman until January 2003, when he was elected Executive Chairman. Mr. Brown served as our Executive Chairman until October 2004. Mr. Brown previously served as the Chairman and Chief Executive Officer of the former Endologix, Inc. since joining that company in 1998. From October 1994 until the sale of the company in September 1997, Mr. Brown served as Chairman, President and Chief Executive Officer at Imagyn Medical, Inc. From 1986 until the sale of the company in 1994, Mr. Brown served as President and Chief Executive Officer of Pharmacia Deltec, Inc., an ambulatory drug delivery company. Mr. Brown also serves on the board of directors of Interventional Spine, Inc., a private medical device company.

Roderick de Greef has served on our Board of Directors since November 2003. Mr. de Greef is the principal of Taveyanne Capital Advisors, Inc., a corporate firm providing finance consulting services. Mr. de Greef served as the Chief Financial Officer of Cambridge Heart from October 2005 to July 2007. Prior to that, Mr. de Greef served as the Executive Vice President, Chief Financial Officer and Secretary of Cardiac Science, Inc. from March 2001 to September 2005. From 1995 to 2001, Mr. de Greef provided corporate finance advisory services to a number of early stage companies including Cardiac Science, where he was instrumental in securing equity capital beginning in 1997, and advising on merger and acquisition activity. From 1989 to 1995, Mr. de Greef was Vice President and Chief Financial Officer of BioAnalogics, Inc. and International BioAnalogics, Inc., both publicly held development stage medical technology companies located in Portland, Oregon. From 1986 to 1989, Mr. de Greef was Controller and then Chief Financial Officer of publicly held Brentwood Instruments, Inc. Mr. de Greef has a B.A. in Economics and International Relations from California State University at San Francisco and an M.B.A. from the University of Oregon. Mr. de Greef serves on the board of BioLife Solutions, Inc., a public biotechnology company located in Owego, New York. Mr. de Greef also serves on the board of ElephantTalk Communications, Inc., an international communications operator based in Orange, California.

Dan Lemaitre has served on our Board of Directors since December 2009. In addition to serving on the Endologix board, Mr. Lemaitre most recently served as the President and CEO of CoreValve, a private company focused on percutaneous aortic valve replacement. CoreValve was acquired in April 2009 for $775 million. Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company's strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years in the medical device field as an investment analyst. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre holds a BA in Economics from Bethany College and an MBA from Bowling Green State University. He also serves on the board of Globus Medical, Inc.

John McDermott is President and Chief Executive Officer and a member of the Endologix Board of Directors. He joined Endologix in 2008 after spending 12 years at C.R. Bard (NYSE: BCR) in various leadership roles including President of Bard Peripheral Vascular, President of Global Sales for Vascular Surgery and Endovascular, and President of IMPRA, Inc. Prior to Bard he was the Chief Operating Officer of IMPRA, a private medical device company that was sold to Bard in 1996. Mr. McDermott joined IMPRA in 1990 as Chief Financial Officer after working for seven years in commercial banking. He is active in the medical device industry and currently serves on the Board of the Directors for the International Society of Endovascular Specialists. Mr. McDermott has three issued U.S. patents, a BS in Finance from Arizona State University, and an MBA from Western International University.

Mr. Guido Neels joined our Board of Directors in December 2010. Mr. Neels is currently Managing Director at Essex Woodlands Health Ventures. Essex Woodlands was the majority shareholder of Nellix, Inc. which was acquired by Endologix on December 10, 2010. Mr. Neels currently holds Board positions at ROX Medical, Inc., Entellus Medical, Oraya Therapeutics, Inc., Arsenal Medical and EndGenitor Technologies. Prior to joining Essex Woodlands in 2006, Mr. Neels served as Chief Operating Officer of Guidant Corporation, a world leader in the development of cardiovascular medical products. He was responsible for the global operations of Guidant's four operating units. He previously served as Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. Prior to joining Guidant, Mr. Neels held various general management, sales and marketing positions at Eli Lilly and Co. and help positions in IT, finance and manufacturing at Raychem Corporation in Belgium and the U.S.

Mr. Neels holds an M.B.A. from Stanford University and a Business Engineering degree from the University of Leuven in Belgium.

Gregory D. Waller has served on our Board of Directors since November 2003. Mr. Waller has been Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories since March, 2006. Previous to that Mr. Waller had been in retirement except for board directorships. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco and Metrex. Mr. Waller joined Ormco in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an MBA with a concentration in accounting from California State University, Fullerton. Mr. Waller also serves on the board of Clarient, Inc., Cardiogenesis Corporation, Alsius Corporation and SenoRx, Inc., all publicly traded companies, where he is the audit committee chairman. He serves on the board of VivoMetrics Corp., a privately-held company.

Thomas Wilder has served on our Board of Directors since May 2010. Mr. Wilder currently serves as President and CEO of Sequent Medical, a private company focused on developing innovative devices for the treatment of neurovascular disease. Prior to joining Sequent Medical, Mr. Wilder was President and CEO of Photothera, a private company developing transcranial laser therapy for the treatment of acute ischemic stroke. Prior to Photothera, Mr. Wilder was President and CEO of Micro Therapeutics, a publicly traded company that provided a broad range of advanced interventional products to neurovascular specialists. Micro Therapeutics was merged into ev3 in January 2006 at a valuation of approximately $360 million. Prior to Micro Therapeutics, Mr. Wilder held several positions during an eleven-year tenure at Medtronic, including Vice President & General Manager, Endovascular Stent Grafts; Vice President, Finance, IT and Business Development at Medtronic Vascular; and roles of increasing responsibility as a five-year expatriate in both Europe and Asia. Mr. Wilder holds a BA in Economics, with distinction, from Stanford University and a Master of Management, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University.

Edward B. Diethrich, M.D. is currently serving as the Medical Director for Endologix. He served on our Board of Directors since May 2002. Dr. Diethrich was a Director for the former Endologix, Inc. from 1997 until its merger with us in May 2002. Dr. Diethrich has been the Medical Director and Chief of Cardiovascular Surgery of the Arizona Heart Hospital since 1997, and has been the Director and Chief of Cardiovascular Surgery at the Arizona Heart Institute from 1971 to the present.